NDAINHALATIONAEROSOL, METERED
Approved
Apr 2023
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
2/8 — Basic
Drug data last refreshed 3d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYMBICORT AEROSPHERE is a metered-dose inhaler containing budesonide (inhaled corticosteroid) and formoterol fumarate (long-acting beta-2 agonist) approved in April 2023. It is indicated for maintenance treatment of asthma and COPD, combining anti-inflammatory and bronchodilator activity. The AeroSphere technology enables improved drug delivery via a propellant-free, breath-actuated aerosol platform.
Growth4.1 years to LOE
Recently approved product in growth phase with expanding market penetration; commercial team building out field force and market share capture initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on SYMBICORT AEROSPHERE at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.